Evidera
Carrie Collins-Cann is an accomplished professional in medical writing and healthcare communications, currently serving as a Senior Manager at Thermo Fisher Scientific and at Evidera. With extensive experience at Fidelity Investments spanning over two decades, Carrie held various leadership roles, including Director of Writing and Communication, where responsibilities included managing large teams and overseeing content strategies for policies and training. Prior roles at companies such as nSight®, Dataquest, Inc., and Interleaf showcase expertise in editorial services, content management, and instructional design. Carrie holds a Bachelor of Arts in English Literature and Anthropology from Smith College and a Master of Arts in Writing and Publishing from Emerson College.
This person is not in any teams
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.